EFUND BIOPHAR ETF

Rongchang Biotech Announces Profitable 2025 Annual Report

Rongchang Biotechnology's RC288 Receives NMPA Approval for Clinical Trials

Shanghai Junyi Le Biotechnology Co., Ltd. Increases Registered Capital to 2.4 Billion Yuan

Canbiopharm Revenue Increases 43.9% in 2025, IVO-3001 FDA Application Accepted

Sanke Biopharmaceutical Reports Significant Growth in 2025 Performance and Global Collaboration with Pfizer

JS Biopharma Chairman Xiong Jun Completes Share Buyback Plan

3SBIO released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 7.292 B, actual EPS HKD 1.5546

3SBIO released FY2025 9-month earnings on March 30, 2026 (BJT), with actual revenue of HKD 12.01 B and EPS of HKD 2.161

Sensing Pharma Reports Significant Profit Growth for FY2025 and Pushes Ahead with Mandi Spin-Off Plans

3SBIO released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 7.417 B, actual EPS HKD 1.5814

3SBIO released FY2025 Annual Earnings on March 30 After-Market (BJT), actual revenue HKD 19.34 B (forecast HKD 20.51 B), actual EPS HKD 3.7488 (forecast HKD 4.3571)

Xiansheng Pharmaceutical Expected to See Significant Growth in Revenue and Net Profit in 2026

Goldman Sachs Releases Performance Analysis Report on Novoheart

CanAngen's Revenue Grew by 43.9% to 3.056 Billion Yuan in 2025

Rongchang Biotechnology Reports Profit of 710 Million Yuan for 2025 Year

INSILICO released FY2025 Q3 earnings on March 29, 2026 (BJT), with actual revenue of HKD 112 M and EPS of HKD -16.1989

INSILICO released FY2025 Annual Earnings on March 29 (BJT), actual revenue HKD 438.54 M (forecast HKD 429.27 M), actual EPS HKD -34.9338 (forecast HKD 0)

INSILICO released FY2025 9 Months Earnings on March 29, 2026 (BJT), with actual revenue of HKD 326.56 M and EPS of HKD -18.1526

INSILICO released FY2025 Q4 earnings on March 29, 2026 (BJT) with actual revenue of HKD 111.96 M and EPS of HKD -16.1929

PUXING ENERGY

STARCOIN GROUP

KNOWLEDGE ATLAS

EASY SMART GP

WORLD SUPER

XL2CSOPSMSN-U

PPS INT'L

LAP KEI ENGRG

CHINA FORTUNE

XL2CSOPSMSN

159837

03032

513700

588860

159849

<p>This week (from March 23 to 27), the Hong Kong stock market experienced fluctuations and differentiation, with the healthcare sector rising against the trend by 3.1%, becoming the only core index to increase. Southbound funds saw significant inflows, with a net purchase exceeding HKD 25 billion. The technology and consumer sectors, part of the new economy, performed relatively weakly, with the Hang Seng SCHK New Economy Index slightly declining by 0.5%. Overall, the capital market is active, with the E Fund Technology ETF attracting over RMB 2 billion in the past month. Investment should be approached with caution</p>

腾讯新闻 - 财经

E Fund CSI Biotechnology Theme ETF

HSTECH ETF

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

CSOP HEALTHCARE

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

ICBCCS SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hang Seng Index

Guotai CSI Bio-medicine ETF

Hang Seng Composite Index

Bosera Hang Seng Health Care ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Dacheng Hang Seng Technology ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Harvest Hang Seng HK Equities New Economy Index Fund(LOF)-A

Hang Seng TECH ETF I

Tianhong Hang Seng TECH ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Hang Seng TECH Index

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

The Hong Kong stock market's new economy sector experienced fluctuations and differentiation throughout the week, with the pharmaceutical sector leading the gains and significant inflows of southbound funds

03069

<p>As of March 24, the pharmaceutical sector has risen against the trend, with several companies such as KEYMED BIO-B and INSILICO showing significant gains. The industry is overall driven by dual engines of CXO pharmaceutical outsourcing services and ADC antibody-drug conjugates, with leading companies maintaining high performance and a stable policy environment. WuXi AppTec expects double-digit revenue growth by 2025, with ADC innovative drugs gradually entering the harvest period, increasing industry concentration, and deepening the competitive moat of leading enterprises. Investors may focus on ETFs in the biotechnology and innovative drug sectors</p>

CAM HSBIOTECH

VanEck Biotech ETF

ALPS Medical Breakthrough

KEYMED BIO-B

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

China Southern CNI HK Connect Innovative Drug ETF

First Trust NYSE Arca Biotech Index Fd

WuXi AppTec

GX CN BIOTECH

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

INSILICO

Direxion S&P Biotech Bull 3X

WUXI APPTEC

CAM HSBIOTECH-R

Hwabao WP CSI Pharmaceuticals ETF

WUXI BIO

China Universal CNI HK Connect Innovative Drugs Industry ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Ark Genomic Revolution ETF

WuXi Biologics

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

CCB Principal CSI Innovative Drugs Industry ETF

SPDR S&P Biotech

iShares US Pharma

The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector

EFUND BIOPHAR ETF(03186.HK)

EFUND BIOPHAR ETF Stock Performance Chart

The Hong Kong stock market's new economy sector experienced fluctuations and differentiation throughout the week, with the pharmaceutical sector leading the gains and significant inflows of southbound funds

The performance of leading pharmaceutical companies continues to validate high prosperity, highlighting the undervalued allocation value of the pharmaceutical and biotechnology sector